WO2003105908A3 - Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs - Google Patents

Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs Download PDF

Info

Publication number
WO2003105908A3
WO2003105908A3 PCT/US2003/007934 US0307934W WO03105908A3 WO 2003105908 A3 WO2003105908 A3 WO 2003105908A3 US 0307934 W US0307934 W US 0307934W WO 03105908 A3 WO03105908 A3 WO 03105908A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
cells
mammal
asialodeterminants
glycoconjugates
Prior art date
Application number
PCT/US2003/007934
Other languages
French (fr)
Other versions
WO2003105908A2 (en
WO2003105908A9 (en
WO2003105908B1 (en
Inventor
Catherine A Phillips
Original Assignee
Dep Veterans Affairs Rehab R&D
Catherine A Phillips
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2004512808A priority Critical patent/JP2006501169A/en
Application filed by Dep Veterans Affairs Rehab R&D, Catherine A Phillips filed Critical Dep Veterans Affairs Rehab R&D
Priority to KR10-2004-7014544A priority patent/KR20050013531A/en
Priority to IL16407903A priority patent/IL164079A0/en
Priority to EP03748896A priority patent/EP1499347A2/en
Priority to CA002479309A priority patent/CA2479309A1/en
Priority to AU2003267949A priority patent/AU2003267949A1/en
Publication of WO2003105908A2 publication Critical patent/WO2003105908A2/en
Publication of WO2003105908A9 publication Critical patent/WO2003105908A9/en
Publication of WO2003105908A3 publication Critical patent/WO2003105908A3/en
Publication of WO2003105908B1 publication Critical patent/WO2003105908B1/en
Priority to US10/940,691 priority patent/US20070110734A9/en
Priority to HK06100051.0A priority patent/HK1079987A1/en
Priority to AU2009201808A priority patent/AU2009201808A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1741—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals alpha-Glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

The present invention is directed to methods for delivering cells to a target tissue in a mammal using glycoconjugate to traffic the cell to a desired organ in the mammal. The methods according to the present invention are especially applicable to administering lymphoid cells such as natural killer (NK) cells activated with interleukin-2 (IL-2), lymphokine-activated killer (LAK) cells and/or tumor-infiltrating lymphocytes (TILs) and/or cytotoxic lymphocytes (CTLs), or stem cells such as those derived from the bone marrow or from umbilical cord tissue. The methods are also useful for targeting a gene of interest to a tissue in a mammal by introducing a cell containing the gene of interest and administering a glycoconjugate to the mammal.
PCT/US2003/007934 2002-03-15 2003-03-14 Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs WO2003105908A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AU2003267949A AU2003267949A1 (en) 2002-03-15 2003-03-14 Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs
KR10-2004-7014544A KR20050013531A (en) 2002-03-15 2003-03-14 Methods and Compositions Using Cellular Asialodeterminants and Glycoconjugates for Targeting Cells to Tissues and Organs
IL16407903A IL164079A0 (en) 2002-03-15 2003-03-14 Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs
EP03748896A EP1499347A2 (en) 2002-03-15 2003-03-14 Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs
CA002479309A CA2479309A1 (en) 2002-03-15 2003-03-14 Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs
JP2004512808A JP2006501169A (en) 2002-03-15 2003-03-14 Methods and compositions for targeting cells to tissues and organs using cellular asialo determinants and glycoconjugates
US10/940,691 US20070110734A9 (en) 2002-03-15 2005-02-01 Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs
HK06100051.0A HK1079987A1 (en) 2002-03-15 2006-01-04 Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs
AU2009201808A AU2009201808A1 (en) 2002-03-15 2009-05-06 Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36449802P 2002-03-15 2002-03-15
US60/364,498 2002-03-15

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/940,691 Continuation US20070110734A9 (en) 2002-03-15 2005-02-01 Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs

Publications (4)

Publication Number Publication Date
WO2003105908A2 WO2003105908A2 (en) 2003-12-24
WO2003105908A9 WO2003105908A9 (en) 2004-03-04
WO2003105908A3 true WO2003105908A3 (en) 2004-10-28
WO2003105908B1 WO2003105908B1 (en) 2004-12-16

Family

ID=28041926

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/US2003/007836 WO2003077865A2 (en) 2002-03-15 2003-03-14 Methods and compositions for directing cells to target organs
PCT/US2003/007934 WO2003105908A2 (en) 2002-03-15 2003-03-14 Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs
PCT/US2003/007834 WO2003077864A2 (en) 2002-03-15 2003-03-14 Methods and compositions for directing cells to target organs

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2003/007836 WO2003077865A2 (en) 2002-03-15 2003-03-14 Methods and compositions for directing cells to target organs

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2003/007834 WO2003077864A2 (en) 2002-03-15 2003-03-14 Methods and compositions for directing cells to target organs

Country Status (10)

Country Link
US (8) US7282222B2 (en)
EP (1) EP1499347A2 (en)
JP (1) JP2006501169A (en)
KR (1) KR20050013531A (en)
CN (1) CN100579577C (en)
AU (4) AU2003225793A1 (en)
CA (1) CA2479309A1 (en)
HK (1) HK1079987A1 (en)
IL (1) IL164079A0 (en)
WO (3) WO2003077865A2 (en)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
US20030032179A1 (en) * 2000-12-06 2003-02-13 Hariri Robert J. Post-partum mammalian placenta, its use and placental stem cells therefrom
AU2002220209B2 (en) 2000-12-06 2006-05-25 Robert J. Hariri Method of collecting placental stem cells
KR101012952B1 (en) * 2001-02-14 2011-02-08 안트로제네시스 코포레이션 Post-partum mammalian placenta, its use and placental stem cells therefrom
WO2003077865A2 (en) * 2002-03-15 2003-09-25 Baxter International Inc. Methods and compositions for directing cells to target organs
EP1622645B1 (en) * 2002-04-23 2013-10-23 Roger Williams Hospital Compositions and methods for stem cell delivery
WO2003106640A2 (en) * 2002-06-14 2003-12-24 Case Western Reserve University Cell targeting methods and compositions
US20050271639A1 (en) * 2002-08-22 2005-12-08 Penn Marc S Genetically engineered cells for therapeutic applications
KR20050062605A (en) * 2002-10-10 2005-06-23 디파트먼트 오브 베테랑스 어페어스 오피스 오브 더 제네럴 카운셀 (024) Detection, localization and staging of tumors using labeled activated lymphocytes directed to a tumor specific epitope
KR101042448B1 (en) 2002-11-26 2011-06-16 안트로제네시스 코포레이션 Cytotherapeutics, cytotherapeutic units and methods for treatments using them
WO2004084950A2 (en) * 2003-03-24 2004-10-07 Case Western Reserve University Cell targeting methods and compositions
ATE482725T1 (en) 2003-04-01 2010-10-15 Us Dept Of Veteran S Affaires STEM CELL, PROGRESSOR CELL OR TARGET CELL BASED TREATMENT OF MULTI-ORGAN FAILURE.
JP2007530543A (en) 2004-03-22 2007-11-01 オシリス セラピューティクス，インコーポレイテッド Mesenchymal stem cells and use thereof
US20060045872A1 (en) 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
CA2583308C (en) * 2004-10-08 2020-01-07 Georgia Tech Research Corporation Microencapsulation of cells in hydrogels using electrostatic potentials
US8703200B2 (en) * 2005-04-29 2014-04-22 The Board Of Regents Of The University Of Oklahoma Inhibition of neovascularization by cerium oxide nanoparticles
FI20055398A0 (en) 2005-07-08 2005-07-08 Suomen Punainen Risti Veripalv Method for evaluating cell populations
ES2452595T3 (en) 2005-10-13 2014-04-02 Anthrogenesis Corporation Immunomodulation using placental stem cells
KR20210122908A (en) 2005-12-29 2021-10-12 안트로제네시스 코포레이션 Placental stem cell populations
AU2006332679A1 (en) 2005-12-29 2007-07-12 Anthrogenesis Corporation Co-culture of placental stem cells and stem cells from a second source
US20070178073A1 (en) * 2006-02-01 2007-08-02 Samsung Life Public Welfare Foundation Composition Comprising Separated or Proliferated Cells from Umbilical Cord Blood for Treating Developmental and/or Chronic Lung Disease
EP2422800A3 (en) 2006-03-07 2013-03-06 Geeta Shroff Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
US7959949B2 (en) 2006-04-27 2011-06-14 University Of Central Florida Research Foundation, Inc. Functionalized nanoceria composition for ophthalmic treatment
EP2094839B1 (en) * 2006-12-08 2020-02-05 University of Rochester Expansion of hematopoietic stem cells
CA2672998C (en) * 2007-01-02 2013-08-06 University Of Central Florida Research Foundation, Inc. Methods and materials for stimulating proliferation of stem cells
FI20075030A0 (en) 2007-01-18 2007-01-18 Suomen Punainen Risti Veripalv Method of modifying cells
US20090104160A1 (en) * 2007-02-01 2009-04-23 Moraga Biotechnology Corporation Mobilization of Stem Cells After Trauma and Methods Therefor
DK2120977T3 (en) 2007-02-12 2013-08-12 Anthrogenesis Corp Treatment of inflammatory diseases using placental stem cells
CA2682469A1 (en) 2007-03-30 2008-10-09 The Cleveland Clinic Foundation Method of treating ischemic disorders
US8574567B2 (en) 2007-05-03 2013-11-05 The Brigham And Women's Hospital, Inc. Multipotent stem cells and uses thereof
EP2607477B1 (en) 2007-05-03 2020-09-23 The Brigham and Women's Hospital, Inc. Multipotent stem cells and uses thereof
US9119391B1 (en) 2007-07-16 2015-09-01 University Of Central Florida Research Foundation, Inc. Polymer coated ceria nanoparticles for selective cytoprotection
EP2591789B2 (en) * 2007-09-19 2022-07-20 Pluristem Ltd. Adherent cells from adipose or placenta tissues and use thereof in therapy
KR20210022148A (en) 2007-09-28 2021-03-02 안트로제네시스 코포레이션 Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
US8142759B2 (en) * 2007-12-12 2012-03-27 Institute Of Nuclear Energy Research Glyco-molecular imaging method for grade classification of liver fibrosis and its glyco-molecular imaging agent thereof
EP2234628B1 (en) 2007-12-14 2017-10-18 The Cleveland Clinic Foundation Compositions and methods of promoting wound healing
US20090246179A1 (en) * 2008-02-11 2009-10-01 The Cleveland Clinic Foundation Method of treating myocardial injury
US8916199B1 (en) 2008-04-25 2014-12-23 University of Central Florida Research Foundation, Ind. Inhibition of angiogenesis associated with ovarian cancer by nanoparticles of cerium oxide
EP2166085A1 (en) 2008-07-16 2010-03-24 Suomen Punainen Risti Veripalvelu Divalent modified cells
US9127202B1 (en) 2008-07-18 2015-09-08 University Of Central Florida Research Foundation, Inc. Biocompatible nano rare earth oxide upconverters for imaging and therapeutics
KR101903049B1 (en) 2008-08-20 2018-11-07 안트로제네시스 코포레이션 Treatment of stroke using isolated placental cells
KR20110050521A (en) 2008-08-20 2011-05-13 안트로제네시스 코포레이션 Improved cell composition and methods of making the same
KR20110050688A (en) 2008-08-22 2011-05-16 안트로제네시스 코포레이션 Methods and compositions for treatment of bone defects with placental cell populations
CN105708862B (en) 2008-09-02 2020-11-06 普拉里斯坦有限公司 Adherent cells from placental tissue and their use in therapy
AU2009316541B2 (en) 2008-11-19 2015-08-06 Celularity Inc. Amnion derived adherent cells
US8470308B2 (en) * 2009-01-03 2013-06-25 Ray C. Wasielewski Enhanced medical implant comprising disrupted tooth pulp and tooth particles
US10328103B2 (en) 2009-01-03 2019-06-25 Ray C. Wasielewski Medical treatment composition comprising mammalian dental pulp stem cells
US8883519B1 (en) 2009-03-17 2014-11-11 University Of Central Florida Research Foundation, Inc. Oxidase activity of polymeric coated cerium oxide nanoparticles
US9585840B1 (en) 2009-07-10 2017-03-07 University Of Central Florida Research Foundation, Inc. Redox active cerium oxide nanoparticles and associated methods
BR112012004395B8 (en) 2009-08-28 2021-05-25 Cleveland Clinic Found stroma cell-derived factor 1 plasmid (sdf-1) and injectable preparation comprising said plasmid
US8795731B1 (en) 2009-10-12 2014-08-05 University Of Central Florida Research Foundation, Inc. Cerium oxide nanoparticle-based device for the detection of reactive oxygen species and monitoring of chronic inflammation
EP3284818B1 (en) 2010-01-26 2022-03-09 Celularity Inc. Treatment of bone-related cancers using placental stem cells
US20130071361A1 (en) * 2010-02-18 2013-03-21 Sanjeev Gupta Methods of treatment of hemophilia
KR20230054905A (en) 2010-04-07 2023-04-25 셀룰래리티 인코포레이티드 Angiogenesis using placental stem cells
WO2011127113A1 (en) 2010-04-08 2011-10-13 Anthrogenesis Corporation Treatment of sarcoidosis using placental stem cells
WO2011159981A2 (en) * 2010-06-18 2011-12-22 Women And Infants Hospital Of Rhode Island Lung regeneration using cord blood-derived hematopoietic stem cells
ES2666746T3 (en) 2010-07-13 2018-05-07 Anthrogenesis Corporation Methods to generate natural cytolytic lymphocytes
US10426740B1 (en) 2010-08-18 2019-10-01 Avm Biotechnology, Llc Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
WO2012036786A1 (en) 2010-09-17 2012-03-22 University Of L'aquila Nanoparticles of cerium oxide targeted to an amyloid-beta antigen of alzheimer's disease
US8969315B2 (en) 2010-12-31 2015-03-03 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules
EP2689008B1 (en) 2011-03-22 2017-09-27 Pluristem Ltd. Methods for treating radiation or chemical injury
PL2714059T3 (en) 2011-06-01 2019-04-30 Celularity Inc Treatment of pain using placental stem cells
US8951539B1 (en) 2011-06-07 2015-02-10 University Of Central Florida Research Foundation, Inc. Methods of promoting angiogenesis using cerium oxide nanoparticles
WO2013055476A1 (en) 2011-09-09 2013-04-18 Anthrogenesis Corporation Treatment of amyotrophic lateral sclerosis using placental stem cells
US9161950B2 (en) 2011-09-21 2015-10-20 University Of Central Florida Foundation, Inc. Neuronal protection by cerium oxide nanoparticles
US9763983B2 (en) 2013-02-05 2017-09-19 Anthrogenesis Corporation Natural killer cells from placenta
US9463437B2 (en) 2013-02-14 2016-10-11 University Of Central Florida Research Foundation, Inc. Methods for scavenging nitric oxide using cerium oxide nanoparticles
CN105079792A (en) * 2014-05-14 2015-11-25 中国科学院上海生命科学研究院 Application of IL-17 in improving mesenchymal stem cell immunity inhibition function
EP3204021A4 (en) * 2014-10-07 2018-03-07 Nutech Medical, Inc. Mesenchymal stem cell diagnostic testing
EP3356415A1 (en) 2015-09-29 2018-08-08 Amgen Inc. Asgr inhibitors
GB201604304D0 (en) 2016-03-14 2016-04-27 Tigenix S A U Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
SG11201907744QA (en) 2017-04-01 2019-09-27 Avm Biotechnology Llc Replacement of cytotoxic preconditioning before cellular immunotherapy
EP3488851A1 (en) 2018-10-03 2019-05-29 AVM Biotechnology, LLC Immunoablative therapies
WO2020142727A1 (en) * 2019-01-03 2020-07-09 Palleon Pharmaceuticals Inc. Methods and compositions for treating cancer with immune cells

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801533A (en) * 1986-06-25 1989-01-31 Fudenberg H Hugh Method of using alpha-1 acid glycoprotein on T-cells as a marker for alzheimer's disease
US5346696A (en) * 1991-06-19 1994-09-13 Korea Green Cross Corporation Asialoglycoprotein - conjugated medicinal agent
WO2000063253A1 (en) * 1999-04-16 2000-10-26 Amgen Inc. Agp-1 fusion protein compositions and methods
WO2001024771A1 (en) * 1999-10-05 2001-04-12 Wood Gary W Composition and method of cancer antigen immunotherapy
WO2003077865A2 (en) * 2002-03-15 2003-09-25 Baxter International Inc. Methods and compositions for directing cells to target organs

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4466951A (en) * 1982-11-12 1984-08-21 University Of California Intracellular trapping of therapeutics or tracer agents
JPS61503003A (en) * 1984-04-19 1986-12-25 ユニバ−シテイ−　オブ　クイ−ンスランド Contraceptive methods, contraceptive preparations and contraceptive devices
US4797368A (en) * 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US4735210A (en) * 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5679323A (en) * 1986-07-03 1997-10-21 Advanced Magnetics, Inc. Hepatocyte-specific receptor-mediated endocytosis-type compositions
US5554386A (en) 1986-07-03 1996-09-10 Advanced Magnetics, Inc. Delivery of therapeutic agents to receptors using polysaccharides
US5342607A (en) * 1986-07-03 1994-08-30 Advanced Magnetics, Inc. Receptor mediated endocytosis type magnetic resonance imaging contrast agents
US5490991A (en) * 1986-07-03 1996-02-13 Advanced Magnetics, Inc. Directed delivery of radioprotectants using a receptor specific carrier
US5284646A (en) * 1986-07-03 1994-02-08 Advanced Magnetics Inc. Hepatocyte specific receptor mediated endocytosis type magnetic resonance imaging contrast agents
US5262176A (en) * 1986-07-03 1993-11-16 Advanced Magnetics, Inc. Synthesis of polysaccharide covered superparamagnetic oxide colloids
US5352432A (en) * 1986-07-03 1994-10-04 Advanced Magnetics, Inc. Hepatocyte specific composition and their use as diagnostic imaging agents
DE3789432T2 (en) * 1986-12-30 1994-10-06 Nihon Mediphysics Co Ltd High molecular compound, consisting of a unit of a compound that leads to the asialoglycoprotein acceptor and a unit of a chelating compound that is chemically bound to it, and their use.
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US5098843A (en) * 1987-06-04 1992-03-24 Calvin Noel M Apparatus for the high efficiency transformation of living cells
US5270199A (en) 1987-08-20 1993-12-14 The Children's Medical Center Corporation Human mannose-binding protein
US5128257A (en) * 1987-08-31 1992-07-07 Baer Bradford W Electroporation apparatus and process
US4859449A (en) 1987-09-14 1989-08-22 Center For Molecular Medicine And Immunology Modified antibodies for enhanced hepatocyte clearance
US4970154A (en) * 1987-10-09 1990-11-13 Baylor College Of Medicine Method for inserting foreign genes into cells using pulsed radiofrequency
US5043260A (en) * 1987-11-02 1991-08-27 Rhode Island Hospital Perfusion device with hepatocytes
US5057301A (en) * 1988-04-06 1991-10-15 Neorx Corporation Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
EP0452457B1 (en) 1989-11-03 1997-08-20 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5279833A (en) * 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5460831A (en) * 1990-06-22 1995-10-24 The Regents Of The University Of California Targeted transfection nanoparticles
US5173414A (en) * 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5837539A (en) * 1990-11-16 1998-11-17 Osiris Therapeutics, Inc. Monoclonal antibodies for human mesenchymal stem cells
US5486359A (en) * 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
ZA922265B (en) * 1991-03-28 1992-12-30 American Cyanamid Co Somatostatin receptor
US5352670A (en) 1991-06-10 1994-10-04 Alberta Research Council Methods for the enzymatic synthesis of alpha-sialylated oligosaccharide glycosides
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
US5545130A (en) * 1992-04-08 1996-08-13 Genetronics, Inc. Flow through electroporation method
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
CA2134773A1 (en) 1992-06-04 1993-12-09 Robert J. Debs Methods and compositions for in vivo gene therapy
US5608060A (en) * 1992-06-09 1997-03-04 Neorx Corporation Biotinidase-resistant biotin-DOTA conjugates
US5616690A (en) * 1992-06-09 1997-04-01 Neorx Corporation Hexose derivatized human serum albumin clearing agents
US5624896A (en) * 1992-06-09 1997-04-29 Neorx Corporation Clearing agents useful in pretargeting methods
US5322682A (en) * 1992-08-06 1994-06-21 The Regents Of The University Of California Method for quantitatively measuring and mapping stored iron in tissue using MRI
US5656609A (en) 1992-09-24 1997-08-12 University Of Connecticut Method of enhancing and/or prolonging expression of gene introduced into a cell using colchicine
WO1994018562A1 (en) * 1993-02-05 1994-08-18 Epigen, Inc. Human carcinoma antigen (hca), hca antibodies, hca immunoassays, methods of imaging and therapy
US5670361A (en) 1993-05-17 1997-09-23 The Regents Of The University Of California HIV-specific ribozymes
US5525503A (en) * 1993-09-28 1996-06-11 Dana-Farber Cancer Institute, Inc. Signal transduction via CD28
US5527884A (en) * 1993-12-21 1996-06-18 President And Fellows Of Harvard College Mediators of chronic allograft rejection and DNA molecules encoding them
US5728518A (en) * 1994-01-12 1998-03-17 The Immune Response Corporation Antiviral poly-and oligonucleotides
US5728399A (en) * 1994-06-29 1998-03-17 University Of Conn. Use of a bacterial component to enhance targeted delivery of polynucleotides to cells
US5512294A (en) * 1994-08-05 1996-04-30 Li; King C. Targeted polymerized liposome contrast agents
US5683866A (en) * 1996-05-09 1997-11-04 Sarkar; Debi P. Process for producing a targeted gene
WO1998000560A2 (en) * 1996-07-02 1998-01-08 Massachusetts Institute Of Technology Method for determining lymphocyte distribution and trafficking in mammals using imaging
US5719020A (en) * 1996-09-25 1998-02-17 Oklahoma Medical Research Foundation 4,7-dialkoxy N-acetylneuraminic acid derivatives and methods for detection of influenza type A and B viruses in clinical specimens
US7282220B1 (en) * 1996-11-05 2007-10-16 Hsing-Wen Sung Genipin-crosslinked gelatin microspheres as drug carrier
EP1634949B1 (en) 1997-05-08 2010-12-15 Oncothyreon Inc. Method for generating activated T-cells and antigen-pulsed antigen-presenting cells
US6466599B1 (en) * 1999-04-07 2002-10-15 Lambda Physik Ag Discharge unit for a high repetition rate excimer or molecular fluorine laser
KR20050062605A (en) * 2002-10-10 2005-06-23 디파트먼트 오브 베테랑스 어페어스 오피스 오브 더 제네럴 카운셀 (024) Detection, localization and staging of tumors using labeled activated lymphocytes directed to a tumor specific epitope

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801533A (en) * 1986-06-25 1989-01-31 Fudenberg H Hugh Method of using alpha-1 acid glycoprotein on T-cells as a marker for alzheimer's disease
US5346696A (en) * 1991-06-19 1994-09-13 Korea Green Cross Corporation Asialoglycoprotein - conjugated medicinal agent
WO2000063253A1 (en) * 1999-04-16 2000-10-26 Amgen Inc. Agp-1 fusion protein compositions and methods
WO2001024771A1 (en) * 1999-10-05 2001-04-12 Wood Gary W Composition and method of cancer antigen immunotherapy
WO2003077865A2 (en) * 2002-03-15 2003-09-25 Baxter International Inc. Methods and compositions for directing cells to target organs
WO2003077864A2 (en) * 2002-03-15 2003-09-25 Department Of Veterans Affairs, Rehabilitation R & D Service Methods and compositions for directing cells to target organs

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CHANG A E ET AL: "ADOPTIVE IMMUNOTHERAPY WITH VACCINE-PRIMED LYMPH NODE CELLS SECONDARILY ACTIVATED WITH ANTI-CD3 AND INTERLEUKIN-2", JOURNAL OF CLINICAL ONCOLOGY, GRUNE AND STRATTON, NEW YORK, NY, US, vol. 15, no. 2, February 1997 (1997-02-01), pages 796 - 807, XP002937156, ISSN: 0732-183X *
CHANG ALFRED E ET AL: "Current status of adoptive immunotherapy of cancer", CRITICAL REVIEWS IN ONCOLOGY-HEMATOLOGY, vol. 22, no. 3, 1996, pages 213 - 228, XP002287919, ISSN: 1040-8428 *
CHEN C-C ET AL: "A gene therapy approach for treating T cell mediated autoimmune diseases", BLOOD, W.B.SAUNDERS COMPAGNY, ORLANDO, FL, US, vol. 97, no. 4, 15 February 2001 (2001-02-15), pages 886 - 894, XP002959194, ISSN: 0006-4971 *
GAO J ET AL: "THE DYNAMIC IN VIVO DISTRIBUTION OF BONE MARROW-DERIVED MESENCHYMAL STEM CELLS AFTER INFUSION", CELLS TISSUES ORGANS, KARGER, BASEL, CH, vol. 169, 2001, pages 12 - 20, XP009026035, ISSN: 1422-6405 *
KOLB H ET AL: "INTERACTIONS BETWEEN NEURAMINIDASE-TREATED LYMPHOCYTES AND LIVER CELLS", ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, SPRING ST., NY, US, vol. 114, 1979, pages 219 - 222, XP009026069, ISSN: 0065-2598 *
KOLB-BACHOFEN V ET AL: "AUTO IMMUNE REACTIONS AGAINST LIVER CELLS BY SYNGENEIC NEURAMINIDASE TREATED LYMPHOCYTES", JOURNAL OF IMMUNOLOGY, vol. 123, no. 6, 1979, pages 2830 - 2834, XP009026071, ISSN: 0022-1767 *
MORITANI MAKI ET AL: "Prevention of adoptively transferred diabetes in nonobese diabetic mice with IL-10-transduced islet-specific Th1 lymphocytes: A gene therapy model for autoimmune diabetes", JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 98, no. 8, 1996, pages 1851 - 1859, XP002152055, ISSN: 0021-9738 *

Also Published As

Publication number Publication date
IL164079A0 (en) 2005-12-18
WO2003105908A2 (en) 2003-12-24
WO2003077865A3 (en) 2004-04-01
EP1499347A2 (en) 2005-01-26
HK1079987A1 (en) 2006-04-21
WO2003077864A3 (en) 2004-04-01
US20070196331A1 (en) 2007-08-23
JP2006501169A (en) 2006-01-12
KR20050013531A (en) 2005-02-04
WO2003077865A2 (en) 2003-09-25
US20070243175A1 (en) 2007-10-18
US20070248577A1 (en) 2007-10-25
CN1649621A (en) 2005-08-03
WO2003105908A9 (en) 2004-03-04
US20100047215A1 (en) 2010-02-25
WO2003077864A2 (en) 2003-09-25
US20040180040A1 (en) 2004-09-16
US20070243174A1 (en) 2007-10-18
AU2003225793A8 (en) 2003-09-29
AU2003225791A8 (en) 2003-09-29
US7563459B2 (en) 2009-07-21
AU2003225791A1 (en) 2003-09-29
US20070110734A9 (en) 2007-05-17
US20070243173A1 (en) 2007-10-18
US7282222B2 (en) 2007-10-16
CA2479309A1 (en) 2003-12-24
AU2003267949A1 (en) 2003-12-31
AU2009201808A1 (en) 2009-05-28
US20060171934A1 (en) 2006-08-03
WO2003105908B1 (en) 2004-12-16
AU2003225793A1 (en) 2003-09-29
CN100579577C (en) 2010-01-13

Similar Documents

Publication Publication Date Title
WO2003105908A3 (en) Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs
SG147305A1 (en) Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis
CA2323073A1 (en) Uses for human non-autologous mesenchymal stem cells
CN111183149A (en) Cytokine conjugates for the treatment of autoimmune diseases
DE60129007D1 (en) REPRODUCTION OF SOFT AND BONE TISSUE FROM MUSCLE PREMATURE CELLS, AND RELATED COMPOSITIONS AND TREATMENT FORMS
WO2004013093A3 (en) Cytotoxic agents containing novel potent taxanes and their therapeutic use
WO2002076285A3 (en) Composition and methods fro the production of biological tissues and tissue constructs
MX2007008255A (en) Tripeptide and tetrapeptide thioethers.
SI2014673T1 (en) Tumour-associated peptides which bind to MHC molecules
BRPI0410185A (en) composition to maintain the viability of an organ and cell
WO2003105757A3 (en) Methods and compositions for milieu-dependent binding of a targeted agent to a target
WO2005086751A3 (en) Combinatorial interleukin-2 muteins
BRPI0413241A (en) monatin table sweetener compositions and methods of making the same
WO2003012060A3 (en) Cellular compositions which facilitate engraftment of hematopoietic stem cells while minimizing the risk of gvhd
CY1114643T1 (en) MODULAR CELLS NM-F9 (DSM ACC2606) AND NM-D4 (DSM ACC2605), USE OF THESE
WO2003025167A3 (en) Cultured stromal cells and uses thereof
AU2002331356A1 (en) Nanoparticles for dna administration to a target organ
BR0312365A (en) Autologous human autologous progenitor mother cell culture medium, methods for the preparation thereof and a composition of human autologous progenitor mother cell and for obtaining autologous human progenitor muscle mother cells, use of an autologous human autologous progenitor culture medium human autologous progenitor mother cells, procedure for obtaining human autologous muscle progenitor mother cells and therapeutic procedure for autologous cell cardiomyoplasty, composition enriched with human autologous muscle progenitor mother cells and pharmaceutical composition
AU8564098A (en) The ha-1 antigen
Eggermont et al. In vivo generation of lymphokine activated killer cell activity by ABPP and interleukin-2 and their antitumor effects against immunogenic and nonimmunogenic tumors in murine tumor models
WO2014007669A1 (en) Autologous cell vaccine for treating oncological diseases and method for producing same
AU2001259744A1 (en) Compositions and methods for producing antigen-presenting cells
Tuttle et al. Adoptive transfer of bryostatin 1-activated T cells provides long-term protection from tumour metastases
WO2023147564A3 (en) Natural killer t-cells and methods of using the same
Stauss et al. Exploiting alloreactivity for tumour immunotherapy.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
COP Corrected version of pamphlet

Free format text: PAGES 1/16-16/16, DRAWINGS, REPLACED BY NEW PAGES 1/16-16/16

WWE Wipo information: entry into national phase

Ref document number: 164079

Country of ref document: IL

Ref document number: 2479309

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004512808

Country of ref document: JP

Ref document number: 1020047014544

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2003267949

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003748896

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20038094266

Country of ref document: CN

B Later publication of amended claims

Effective date: 20041029

WWP Wipo information: published in national office

Ref document number: 2003748896

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10940691

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1020047014544

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 10940691

Country of ref document: US